Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMYJMV9)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
abt-702; Abt 702; ABT702; CHEMBL66089; UNII-2P206WS5B3; 2P206WS5B3; 5-(3-bromophenyl)-7-[6-(morpholin-4-yl)pyridin-3-yl]pyrido[2,3-d]pyrimidin-4-amine; 5-(3-Bromo-phenyl)-7-(6-morpholin-4-yl-pyridin-3-yl)-pyrido[2,3-d]pyrimidin-4-ylamine; AC1L1CN5; SCHEMBL1914142; GTPL5131; CTK5I8409; MolPort-035-936-400; CHEBI:104129; ZINC21288919; BDBM50094703; AKOS030589605; SMP2_000264; NCGC00092381-03; NCGC00092381-02; LS-134028; BRD-K36021395-300-01-6; 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||
|
||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Bone
Osteosarcoma
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Kidney
Normal (Immortalized)
Liver
Hepatoblastoma
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
